Overview of the renin-angiotensin system in diabetic nephropathy
Diabetes mellitus is a multifactorial hyperglycemic condition characterized by biochemical,
molecular, and genetic variables, and leads to kidney dysfunction. Diabetic nephropathy …
molecular, and genetic variables, and leads to kidney dysfunction. Diabetic nephropathy …
Causal role of immune cells in diabetic nephropathy: a bidirectional Mendelian randomization study
SY Wang, Y Yu, XL Ge, S Pan - Frontiers in Endocrinology, 2024 - frontiersin.org
Background Diabetic nephropathy (DN) stands as a pervasive chronic renal disease
worldwide, emerging as the leading cause of renal failure in end-stage renal disease. Our …
worldwide, emerging as the leading cause of renal failure in end-stage renal disease. Our …
Preclinical pharmacology and pharmacokinetics of curcumin tagged cilostazol nanodispersion for the management of diabetic nephropathy in wister rat model
To evaluate the therapeutic potential of curcumin tagged cilostazol solid nano dispersion in
wistar rat streptozotocin-nicotinamide-induced diabetic nephropathy. Cilostazol (CLT), a …
wistar rat streptozotocin-nicotinamide-induced diabetic nephropathy. Cilostazol (CLT), a …
Anti-apoptosis of podocytes and pro-apoptosis of mesangial cells for telmisartan in alleviating diabetic kidney injury
X Wei, Y Ma, Y Li, W Zhang, Y Zhong, Y Yu… - Frontiers in …, 2022 - frontiersin.org
Podocytes damage and mesangial cells expansion are two important pathological
manifestations of glomerular injury in early diabetes. Telmisartan, as an angiotensin type 1 …
manifestations of glomerular injury in early diabetes. Telmisartan, as an angiotensin type 1 …
A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects
X Liu, X Dai, X Yu, H Zhou, J Xie - Clinical Pharmacology in …, 2024 - Wiley Online Library
Azilsartan is an angiotensin II receptor blocker used for treating adult hypertension. It
significantly improves cardiovascular outcomes in patients with high‐risk hypertension, heart …
significantly improves cardiovascular outcomes in patients with high‐risk hypertension, heart …